Humacyte, Inc. (HUMA) shareholders
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.60+0.00 (+0.63%)
Close on Nov 12, 2026Market cap $165.40MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
26.4%
73M of 278M shares
Institutional holders
162
38 new, 33 sold out
Net institutional buying
14M
In Q2 2026
Insider trades, 12 months
5 buys · 2 sales
Net bought $7.39K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fresenius Medical Care Holdings, Inc. Joint filing with Fresenius Medical Care AG (6.80%) | 18,312,735 | 6.80% | 13D (active) amendment | Jul 10, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HUMA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 10,107,679 | 3.64% | $7.88M | +2,949,517 | 0.00% |
| ANTIPODES PARTNERS Ltd | 10,103,647 | 3.64% | $7.88M | +4,379,897 | 0.14% |
| Alyeska Investment Group, L.P. | 6,022,925 | 2.17% | $4.70M | New | 0.01% |
| Davidson Kempner Capital Management LP | 5,000,000 | 1.80% | $3.90M | New | 0.05% |
| BlackRock, Inc. | 4,839,929 | 1.74% | $3.78M | −7,477,026 | 0.00% |
| Great Point Partners LLC | 3,750,000 | 1.35% | $2.93M | – | 0.55% |
| UBS Group AG | 2,843,493 | 1.02% | $2.22M | +61,423 | 0.00% |
| Aqr Capital Management LLC | 2,597,134 | 0.93% | $2.03M | +672,443 | 0.00% |
| Geode Capital Management, LLC | 2,185,225 | 0.79% | $1.71M | −1,472,883 | 0.00% |
| Millennium Management LLC | 1,909,049 | 0.69% | $1.49M | +1,800,895 | 0.00% |
| Susquehanna International Group, Llp | 1,699,243 | 0.61% | $1.33M | +641,195 | 0.00% |
| Citadel Advisors LLC | 1,443,376 | 0.52% | $1.13M | New | 0.00% |
| Charles Schwab Investment Management Inc | 1,353,515 | 0.49% | $1.06M | +62,170 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,181,276 | 0.43% | $921.40K | +170,247 | 0.00% |
| Hrt Financial LP | 1,089,508 | 0.39% | $850.00K | New | 0.00% |
| LPL Financial LLC | 1,025,535 | 0.37% | $800.33K | +161,072 | 0.00% |
| Gsa Capital Partners Llp | 1,005,709 | 0.36% | $785.00K | +755,853 | 0.05% |
| Private Advisor Group, LLC | 965,091 | 0.35% | $753.16K | +132,292 | 0.00% |
| State Street Corp | 842,537 | 0.30% | $657.52K | −2,201,392 | 0.00% |
| Hbk Investments L P | 790,000 | 0.28% | $616.52K | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 162 | 73M | 26.4% | 38 / 56 | 37 / 33 | 32M | 17M |
| Q1 2026 | 159 | 59M | 21.3% | 35 / 54 | 29 / 19 | 25M | 13M |
| Q4 2025 | 147 | 55M | 19.9% | 23 / 54 | 37 / 15 | 13M | 3M |
| Q3 2025 | 141 | 46M | 16.5% | 16 / 41 | 45 / 29 | 3M | 14M |
| Q2 2025 | 156 | 57M | 20.5% | 31 / 72 | 27 / 40 | 17M | 21M |
| Q1 2025 | 168 | 61M | 21.9% | 39 / 57 | 37 / 31 | 24M | 4M |
| Q4 2024 | 162 | 42M | 15.2% | 46 / 53 | 38 / 25 | 11M | 4M |
| Q3 2024 | 143 | 36M | 12.9% | 36 / 53 | 25 / 15 | 16M | 4M |
| Q2 2024 | 123 | 31M | 11.3% | 46 / 50 | 16 / 17 | 15M | 7M |
| Q1 2024 | 95 | 24M | 8.5% | 17 / 29 | 32 / 10 | 8M | 2M |
| Q4 2023 | 88 | 18M | 6.5% | 11 / 35 | 17 / 6 | 2M | 1M |
| Q3 2023 | 83 | 17M | 6.0% | 16 / 38 | 12 / 8 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
101 funds held HUMA in Q1 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of HUMA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 7,716,766 | 2.78% | $6.02M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,122,919 | 0.76% | $1.66M | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,440,479 | 0.52% | $1.12M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 839,278 | 0.30% | $1.09M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 835,684 | 0.30% | $1.09M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 728,581 | 0.26% | $947.16K | 0.00% | May 31, 2026 |
| Modern Capital Tactical Income Fund | 589,581 | 0.21% | $460.11K | 0.68% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 474,574 | 0.17% | $616.95K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 415,181 | 0.15% | $271.28K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 276,545 | 0.10% | $359.51K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 243,339 | 0.09% | $159.00K | 0.01% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 233,838 | 0.08% | $303.99K | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 167,033 | 0.06% | $130.35K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 160,000 | 0.06% | $124.86K | 0.08% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 136,276 | 0.05% | $106.35K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Laura E. Niklason | President, CEO and Director | 1,392,091 | 0.50% | Jun 12, 2026 |
| Shamik J. Parikh | Chief Medical Officer | 272,713 | 0.10% | May 20, 2026 |
| Dale A. Sander | CFO and Chief Corp. Dev. Off | 307,813 | 0.11% | May 20, 2026 |
| William John Scheessele | Chief Commercial Officer | 22,018 | 0.01% | Apr 15, 2025 |
| Heather Ledbetter Prichard | Chief Operating Officer | 0 | – | Jan 23, 2025 |
| Yang Cao | Chief Regulatory Officer | – | – | Jan 23, 2025 |
| Paul Brian Kuznik | Director | 222,238 | 0.08% | Oct 7, 2026 |
| D. Scott Coward | Director | – | – | Oct 7, 2026 |
| Keith Anthony Jones | Director | 50,000 | 0.02% | Sep 15, 2026 |
| Emery N. Brown | Director | – | – | Jun 12, 2026 |
| Kathleen Sebelius | Director | 148,025 | 0.05% | Jun 12, 2026 |
| Brady W. Dougan | Director | 1,392,091 | 0.50% | Jun 12, 2026 |
| Max N. Wallace | Director | 64,555 | 0.02% | Jun 12, 2026 |
| Susan Richards Windham-Bannister | Director | – | – | Jun 12, 2026 |
| Michael T. Constantino | Director | 43,950 | 0.02% | Jun 12, 2026 |
| Diane Seimetz | Director | – | – | Jun 12, 2026 |
| John Philip Bamforth | Director | – | – | Jun 12, 2026 |
| Charles Bruce Green | Director | 8,400 | 0.00% | Jun 12, 2026 |
| Todd Pope | Director | – | – | Jun 16, 2025 |
| Medical Care Holdings Inc /Ny/ Fresenius | – | 18,312,735 | 6.59% | Dec 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Keith Anthony Jones Director | Sep 14, 2026 | Buy | +10,000 | $0.56 | $5.60K | 50,000 |
| Keith Anthony Jones Director | Aug 20, 2026 | Buy | +10,000 | $0.69 | $6.90K | 40,000 |
| Keith Anthony Jones Director | Aug 17, 2026 | Buy | +30,000 | $0.59 | $17.70K | 30,000 |
| Kathleen Sebelius Director | May 19, 2026 | Buy | +56,818 | $0.88 | $50.00K | 148,025 |
| Michael T. Constantino Director | May 18, 2026 | Buy | +11,000 | $0.89 | $9.79K | 43,950 |
| Dale A. Sander CFO and Chief Corp. Dev. Off | May 18, 2026 | Sale(10b5-1 plan) | −45,887 | $0.90 | $41.30K | 267,213 |
| Shamik J. Parikh Chief Medical Officer | May 18, 2026 | Sale(10b5-1 plan) | −45,887 | $0.90 | $41.30K | 272,713 |
| Dale A. Sander CFO and Chief Corp. Deve. Off. | Nov 16, 2025 | Award | +311,100 | – | – | 313,100 |
| Shamik J. Parikh Chief Medical Officer | Nov 16, 2025 | Award | +311,100 | – | – | 318,600 |
| Brady W. Dougan Director | Aug 20, 2025 | Sale | −591,685 | $1.58 | $934.86K | 0 |
| Laura E. Niklason President, CEO and Director | Aug 20, 2025 | Sale | −591,685 | $1.58 | $934.86K | 0 |
| Brady W. Dougan Director | Aug 19, 2025 | Sale | −1,100,000 | $1.63 | $1.79M | 591,685 |
| Laura E. Niklason President, CEO and Director | Aug 19, 2025 | Sale | −1,100,000 | $1.63 | $1.79M | 591,685 |
| Brady W. Dougan Director | Aug 18, 2025 | Sale | −549,360 | $1.83 | $1.01M | 1,691,685 |
| Laura E. Niklason President, CEO and Director | Aug 18, 2025 | Sale | −549,360 | $1.83 | $1.01M | 1,691,685 |
| William John Scheessele Chief Commercial Officer | Apr 14, 2025 | Buy | +6,493 | $1.54 | $10.00K | 22,018 |
| Dale A. Sander CFO and Chief Corp. Deve. Off. | Apr 10, 2025 | Buy | +20,000 | $1.53 | $30.60K | 40,600 |
| Shamik J. Parikh Chief Medical Officer | Apr 10, 2025 | Buy | +7,500 | $1.55 | $11.63K | 7,500 |
| Charles Bruce Green Director | Apr 8, 2025 | Buy | +6,000 | $1.29 | $7.74K | 8,400 |
| Kathleen Sebelius Director | Apr 8, 2025 | Buy | +50,000 | $1.32 | $66.00K | 91,207 |
| Michael T. Constantino Director | Apr 7, 2025 | Buy | +16,000 | $1.26 | $20.16K | 32,950 |
| Michael T. Constantino Director | Dec 4, 2024 | Buy | +4,600 | $4.39 | $20.19K | 16,950 |
| Brady W. Dougan Director | Nov 20, 2024 | Sale | −261,369 | $4.40 | $1.15M | 1,730,884 |
| Laura E. Niklason President, CEO and Director | Nov 20, 2024 | Sale | −261,369 | $4.40 | $1.15M | 1,730,884 |
| Laura E. Niklason President, CEO and Director | Nov 19, 2024 | Buy | +1,797 | $4.44 | $7.98K | 243,851 |
| Brady W. Dougan Director | Nov 19, 2024 | Buy | +1,797 | $4.44 | $7.98K | 243,851 |
| Brady W. Dougan Director | Nov 19, 2024 | Sale | −427,459 | $4.34 | $1.86M | 1,992,253 |
| Laura E. Niklason President, CEO and Director | Nov 19, 2024 | Sale | −427,459 | $4.34 | $1.86M | 1,992,253 |
| Brady W. Dougan Director | Nov 18, 2024 | Sale | −811,172 | $4.44 | $3.60M | 2,419,712 |
| Laura E. Niklason President, CEO and Director | Nov 18, 2024 | Sale | −811,172 | $4.44 | $3.60M | 2,419,712 |
| Charles Bruce Green Director | Sep 13, 2024 | Option exercise | +1,200 | $4.09 | $4.91K | 2,400 |
| Kathleen Sebelius Director | Sep 10, 2024 | Sale | −3,634 | $5.41 | $19.66K | 40,276 |
| Kathleen Sebelius Director | Sep 10, 2024 | Option exercise | +4,521 | $4.34 | $19.62K | 43,910 |
| Kathleen Sebelius Director | Sep 10, 2024 | Option exercise | +2,479 | $3.35 | $8.30K | 42,755 |
| Kathleen Sebelius Director | Sep 10, 2024 | Sale | −1,548 | $5.39 | $8.34K | 41,207 |
| Brady W. Dougan Director | Sep 10, 2024 | Sale | −288,674 | $5.23 | $1.51M | 3,230,884 |
| Laura E. Niklason President, CEO and Director | Sep 10, 2024 | Sale | −288,674 | $5.23 | $1.51M | 3,230,884 |
| Brady W. Dougan Director | Sep 9, 2024 | Sale | −157,704 | $5.42 | $854.76K | 3,519,558 |
| Laura E. Niklason President, CEO and Director | Sep 9, 2024 | Sale | −157,704 | $5.42 | $854.76K | 3,519,558 |
| Laura E. Niklason President, CEO and Director | Aug 29, 2024 | Buy | +1,222 | $6.55 | $8.00K | 242,054 |
| Brady W. Dougan Director | Aug 29, 2024 | Buy | +1,222 | $6.55 | $8.00K | 242,054 |
| Laura E. Niklason President, CEO and Director | Aug 29, 2024 | Sale | −352,112 | $6.35 | $2.24M | 3,677,262 |
| Brady W. Dougan Director | Aug 29, 2024 | Sale | −352,112 | $6.35 | $2.24M | 3,677,262 |
| Laura E. Niklason President, CEO and Director | Aug 28, 2024 | Sale | −277,090 | $6.47 | $1.79M | 4,029,374 |
| Brady W. Dougan Director | Aug 28, 2024 | Sale | −277,090 | $6.47 | $1.79M | 4,029,374 |
| Dale A. Sander CFO and Chief Corp. Deve. Off. | Aug 27, 2024 | Option exercise | +39,389 | $2.56 | $100.84K | 41,389 |
| Dale A. Sander CFO and Chief Corp. Deve. Off. | Aug 27, 2024 | Sale | −39,389 | $6.68 | $263.12K | 2,000 |
| Laura E. Niklason President, CEO and Director | Aug 27, 2024 | Sale | −252,676 | $6.71 | $1.70M | 4,306,464 |
| Brady W. Dougan Director | Aug 27, 2024 | Sale | −252,676 | $6.71 | $1.70M | 4,306,464 |
| Michael T. Constantino Director | Aug 15, 2024 | Buy | +3,100 | $6.29 | $19.50K | 12,350 |
| Kathleen Sebelius Director | Jun 14, 2024 | Option exercise | +39,389 | $2.56 | $100.84K | 39,389 |
| Brady W. Dougan Director | Jun 12, 2024 | Sale | −271,518 | $7.30 | $1.98M | 4,559,140 |
| Laura E. Niklason President, CEO and Director | Jun 12, 2024 | Sale | −271,518 | $7.30 | $1.98M | 4,559,140 |
| Brady W. Dougan Director | Jun 11, 2024 | Sale | −76,630 | $7.02 | $537.94K | 4,830,658 |
| Brady W. Dougan Director | Jun 11, 2024 | Sale | −282,000 | $7.09 | $2.00M | 4,907,288 |
| Laura E. Niklason President, CEO and Director | Jun 11, 2024 | Sale | −282,000 | $7.09 | $2.00M | 4,907,288 |
| Laura E. Niklason President, CEO and Director | Jun 11, 2024 | Sale | −76,630 | $7.02 | $537.94K | 4,830,658 |
| Brady W. Dougan Director | Jun 4, 2024 | Buy | +2,362 | $6.35 | $15.00K | 240,832 |
| Laura E. Niklason President, CEO and Director | Jun 4, 2024 | Sale | −1,852 | $7.28 | $13.48K | 5,189,288 |
| Brady W. Dougan Director | Jun 4, 2024 | Sale | −1,852 | $7.28 | $13.48K | 5,189,288 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
10.98%
28M shares short
Days to cover
7.2
At 4M shares a day
Change since last report
-7.2%
From 30M shares
Short volume, 20 days
55.7%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Humacyte's stock actually held short. Settlement fails (shares not delivered on time) peaked at 594,794 shares on Sep 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shamik J. Parikh Officer | May 18, 2026 | 45,887 | $41.15K | May 18, 2026 | Restricted Stock Vesting |
| Dale A. Sander Officer | May 18, 2026 | 45,887 | $41.15K | May 18, 2026 | Restricted Stock Vesting |
| Ayabudge LLC Director | Aug 20, 2025 | 591,685 | $936.65K | Aug 20, 2025 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Ayabudge LLC Director | Aug 19, 2025 | 1,100,000 | $1.79M | Aug 19, 2025 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Ayabudge LLC Director | Aug 18, 2025 | 549,360 | $1.00M | Aug 18, 2025 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Ayabudge LLC Director | Nov 20, 2024 | 261,369 | $1.15M | Nov 20, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Ayabudge LLC Director | Nov 19, 2024 | 427,459 | $1.85M | Nov 19, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Ayabudge LLC Director | Nov 18, 2024 | 811,172 | $3.60M | Nov 18, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Kathleen Sebelius Director | Sep 10, 2024 | 5,182 | $28.01K | Sep 10, 2024 | Options Granted - 06/15/2023 |
| Ayabudge LLC Director | Sep 10, 2024 | 288,674 | $1.51M | Sep 10, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Ayabudge LLC Director | Sep 9, 2024 | 157,704 | $855.15K | Sep 9, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Ayabudge LLC Director | Aug 29, 2024 | 352,112 | $2.24M | Aug 29, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES VIA SPAC WHEN THE COMPANY WENT PUBLIC IN 2021. |
| Ayabudge LLC Director | Aug 28, 2024 | 277,090 | $1.79M | Aug 28, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES VIA SPAC WHEN THE COMPANY WENT PUBLIC IN 2021. |
| Ayabudge LLC Director | Aug 27, 2024 | 252,676 | $1.70M | Aug 27, 2024 | EARLY STAGE INVESTOR IN AHAC. AHAC SHARES WERE CONVERTED TO HUMA SHARES VIA SPAC WHEN THE COMPANY WENT PUBLIC IN 2021. |
| Dale A. Sander Officer | Aug 27, 2024 | 39,389 | $263.31K | Aug 27, 2024 | Options Granted 09/01/2015 |
See a number that looks wrong?